Microbot Medical (MBOT) Stock Price, News & Analysis

Company Overview

Microbot Medical Inc. (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease. The endoluminal platform targets gastrointestinal and urogenital tracts, employing swallowable or catheter-deployed microbots to biopsy tissue, administer local therapy or assist in endoscopic procedures.

Headquartered in Ra’anana, Israel, with U.S. operations in Boston, Massachusetts, Microbot Medical collaborates with leading academic and clinical research centers to advance its pipeline through preclinical studies and early-stage human trials. Under the leadership of CEO Ohad Arazi, the company seeks regulatory approvals and strategic partnerships to bring its microbot platforms to global markets in Europe, North America and Asia.

Key Stats

• Today's Range: $3.64 to $4.25
• 50-Day Range: $2.45 to $4.50
• 52-Week Range: $0.85 to $4.67
• Volume: 8.85 million shs
• Average Volume: 5.88 million shs
• Market Capitalization: $177.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Microbot Medical Stock Analysis - MarketRank™

Microbot Medical scored higher than 48% of companies evaluated by MarketBeat, and ranked 643rd out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Microbot Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Microbot Medical has a consensus price target of $12.00, representing about 208.5% upside from its current price of $3.89.

Amount of Analyst Coverage

Microbot Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Microbot Medical are expected to grow in the coming year, from ($0.71) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Microbot Medical is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Microbot Medical is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Microbot Medical has a P/B Ratio of 22.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.24% of the float of Microbot Medical has been sold short.

Short Interest Ratio / Days to Cover

Microbot Medical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Microbot Medical has recently decreased by 3.36%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Microbot Medical does not currently pay a dividend.

Dividend Growth

Microbot Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.24% of the float of Microbot Medical has been sold short.

Short Interest Ratio / Days to Cover

Microbot Medical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Microbot Medical has recently decreased by 3.36%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.83

News Sentiment

Microbot Medical has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Microbot Medical this week, compared to 2 articles on an average week.

Search Interest

63 people have searched for MBOT on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

9 people have added Microbot Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Microbot Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.74% of the stock of Microbot Medical is held by insiders.

Percentage Held by Institutions

Only 16.30% of the stock of Microbot Medical is held by institutions.

MBOT Stock Analysis - Frequently Asked Questions

How have MBOT shares performed this year?

Microbot Medical's stock was trading at $1.12 at the beginning of 2025. Since then, MBOT shares have increased by 247.3% and is now trading at $3.89.

How were Microbot Medical's earnings last quarter?

Microbot Medical Inc. (NASDAQ:MBOT) posted its quarterly earnings results on Tuesday, August, 12th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02.

When did Microbot Medical's stock split?

Shares of Microbot Medical reverse split before market open on Monday, May 9th 2016.The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 6th 2016. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Microbot Medical's major shareholders?

Microbot Medical's top institutional shareholders include Geode Capital Management LLC (1.09%), DNB Asset Management AS (0.53%), Lazari Capital Management Inc. (0.06%) and XTX Topco Ltd (0.05%).
View institutional ownership trends.

How do I buy shares of Microbot Medical?

Shares of MBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Microbot Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Microbot Medical investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), TransEnterix (TRXDW), Pfizer (PFE), Plug Power (PLUG) and Novavax (NVAX).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MBOT
• CIK: 883975
• Web: www.microbotmedical.com
• Phone: (781) 875-3605
• Fax: 781-556-5347
• Employees: 20
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Microbot Medical: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +208.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -76.27%
• Return on Assets: -67.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.06
• Quick Ratio: 12.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 22.88

Miscellaneous

• Outstanding Shares: 45,546,000
• Free Float: 43,387,000
• Market Cap: $177.17 million
• Optionable: Optionable
• Beta: 1.22